Old West Investment Management LLC reduced its stake in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) by 49.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,694 shares of the biotechnology company’s stock after selling 9,316 shares during the quarter. Old West Investment Management LLC’s holdings in Atara Biotherapeutics were worth $378,000 as of its most recent filing with the SEC.
Other hedge funds also recently bought and sold shares of the company. Riverhead Capital Management LLC acquired a new stake in shares of Atara Biotherapeutics during the first quarter worth approximately $100,000. SG Americas Securities LLC acquired a new stake in shares of Atara Biotherapeutics during the first quarter worth approximately $107,000. Principal Financial Group Inc. acquired a new stake in Atara Biotherapeutics in the first quarter valued at approximately $214,000. MetLife Investment Advisors LLC acquired a new stake in Atara Biotherapeutics in the fourth quarter valued at approximately $217,000. Finally, Teacher Retirement System of Texas acquired a new stake in Atara Biotherapeutics in the first quarter valued at approximately $260,000. Institutional investors and hedge funds own 98.37% of the company’s stock.
Atara Biotherapeutics traded up $0.55, reaching $45.60, during trading on Monday, according to Marketbeat Ratings. The company’s stock had a trading volume of 9,757 shares, compared to its average volume of 549,976. The stock has a market capitalization of $1.98 billion, a PE ratio of -11.26 and a beta of 2.61. Atara Biotherapeutics Inc has a 1-year low of $12.15 and a 1-year high of $54.45.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.92) by ($0.13). analysts expect that Atara Biotherapeutics Inc will post -4.06 EPS for the current fiscal year.
In other news, EVP Mitchall G. Clark sold 25,860 shares of the business’s stock in a transaction on Friday, May 18th. The shares were sold at an average price of $50.03, for a total value of $1,293,775.80. Following the completion of the sale, the executive vice president now directly owns 107,972 shares in the company, valued at $5,401,839.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Derrell Porter sold 1,544 shares of the business’s stock in a transaction on Tuesday, May 8th. The stock was sold at an average price of $40.15, for a total transaction of $61,991.60. Following the completion of the sale, the senior vice president now owns 12,500 shares of the company’s stock, valued at $501,875. The disclosure for this sale can be found here. Insiders sold 151,671 shares of company stock valued at $6,685,316 over the last 90 days. 10.60% of the stock is owned by corporate insiders.
A number of analysts have issued reports on the stock. Canaccord Genuity reiterated a “buy” rating and issued a $70.00 target price on shares of Atara Biotherapeutics in a research note on Tuesday, May 8th. Guggenheim assumed coverage on shares of Atara Biotherapeutics in a research note on Thursday, March 15th. They issued a “neutral” rating for the company. BidaskClub upgraded shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, April 26th. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating and set a $45.00 target price for the company in a research note on Tuesday, May 1st. Finally, JMP Securities cut shares of Atara Biotherapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $43.33.
Atara Biotherapeutics Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.